Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.
Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.
We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.
Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.
By the time Abbey Meyers, founder of the National Organization for Rare Disorders (NORD) and chief architect of the ODA, wrote her letter to me a few years later, the paradoxical conflict of orphan-drug availability versus price had become obvious.
These are the stories of longtime leaders, still active in the industry, sharing their historical perspectives on innovation in the life sciences industry. This month: Why David Hale is considered an icon of entrepreneurial biotech.
The chairman of Bristol-Myers summoned the head of R&D into his office. “Bill, go down and check out the ruckus on the street,” he said. “Something about our new AIDS drug.” When Dr. William Comer exited the front door of the company’s New York City headquarters, he saw a small group of men marching around on the sidewalk, holding signs, blowing trumpets, beating drums, and chanting loudly.
Three top biopharmaceutical executives share their ideas on what bio clusters biopharmaceutical executives should be paying attention to for 2018. In addition, insights are provided on other future potential bio hot spots.
Five top biopharmaceutical executives share their thoughts on Big Data, industry trends, personalized medicine, and more in preparing you for what to expect in 2018 – and beyond.
Five female biopharmaceutical industry CEOs share exclusive insights on what to expect for 2018 and beyond.
A behind the scenes look into the educational planning for the 2018 BIO International Convention in Boston.
In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.